High materiality9/10
PTC Therapeutics assumed with a Buy at UBS
Why it may matterVerify against the original reporting
Positive upgrade with substantial upside.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS target update on PTCT: target $90, current price $59.67, implied upside ~51%.
- UBS target: $90
- Current price: $59.67
- Upside: ~51%
Key facts
- 01
Target: $90
- 02
Posted price: $59.67
- 03
Analyst firm: UBS
- 04
Analyst: Joon Lee
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.